Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Nelli Roininen"'
Autor:
Peeter Karihtala, Katja Porvari, Nelli Roininen, Sari Voutilainen, Johanna Mattson, Päivi Heikkilä, Kirsi-Maria Haapasaari, Katri Selander
Publikováno v:
Oncogenesis, Vol 11, Iss 1, Pp 1-11 (2022)
Abstract The pathophysiology and the optimal treatment of breast neuroendocrine tumours (NETs) are unknown. We compared the mutational profiles of breast NETs (n = 53) with those of 724 publicly available invasive ductal carcinoma (IDC) and 98 pancre
Externí odkaz:
https://doaj.org/article/2af5b7589630403baeb90a0af5c02b58
Publikováno v:
BMJ Open, Vol 11, Iss 1 (2021)
Objectives Being either young or old at the time of breast cancer diagnosis has been suggested as an indicator of a poor prognosis. We studied the effect of age at breast cancer onset in relation to survival, focusing in particular on biological subt
Externí odkaz:
https://doaj.org/article/6b9089d72b1648dd83ab53281f3886b1
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
While breast cancer prognoses are generally good, different molecular subtypes are known to have varying outcomes. Previous studies using breast cancer registries have suggested that high parity may be an adverse prognostic factor in luminal breast c
Externí odkaz:
https://doaj.org/article/913554e4d5cd45d1a5b533a9955ca9a0
Publikováno v:
Acta oncologica (Stockholm, Sweden). 61(4)
Background: There is very limited data available on how most breast cancer recurrences, either distant metastases or locoregional recurrences (LRR), are actually discovered in routine clinical practice. Patients and methods: From a prospective cohort
Autor:
Peeter Karihtala, Katja Porvari, Nelli Roininen, Sari Voutilainen, Johanna Mattson, Päivi Heikkilä, Kirsi-Maria Haapasaari, Katri Selander
Publikováno v:
Oncogenesis. 11(1)
The pathophysiology and the optimal treatment of breast neuroendocrine tumours (NETs) are unknown. We compared the mutational profiles of breast NETs (n = 53) with those of 724 publicly available invasive ductal carcinoma (IDC) and 98 pancreatic NET
Publikováno v:
Annals of Oncology. 32:S81-S82
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
While breast cancer prognoses are generally good, different molecular subtypes are known to have varying outcomes. Previous studies using breast cancer registries have suggested that high parity may be an adverse prognostic factor in luminal breast c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c7a446ab6ab769c2005912ccc506163
http://urn.fi/urn:nbn:fi-fe2020120198873
http://urn.fi/urn:nbn:fi-fe2020120198873
Autor:
K. Selander, P. Karihtala, K.-M. Haapasaari, J. Mattson, S. Voutilainen, Nelli Roininen, K. Porvari, Päivi Heikkilä
Publikováno v:
Annals of Oncology. 32:S413
Publikováno v:
Oxidative Medicine and Cellular Longevity, Vol 2017 (2017)
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity
Although validated predictive factors for breast cancer chemoresistance are scarce, there is emerging evidence that the induction of certain redox-regulating enzymes may contribute to a poor chemotherapy effect. We investigated the possible associati
Publikováno v:
BMJ Open
BMJ Open, Vol 10, Iss 10 (2020)
BMJ Open, Vol 10, Iss 10 (2020)
ObjectivesAlthough novel early breast cancer prognostic factors are being continuously discovered, only rare factors predicting survival in metastatic breast cancer have been validated. The prognostic role of early breast cancer prognostic factors in